| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Despite recent medical developments, some severe eye diseases still have no effective therapy. These diseases include retinitis pigmentosa (RP), which is characterized by a gradual loss of photoreceptors which can cause night blindness and visual field defects and even lead to blindness under severe conditions. Artificial vision is one of the several therapeutic attempt for RP. We evaluated the efficacy of new electrode for our artificial vision system. We established the experimental system for evaluating the efficacy of artificial vision in rats and found that our half diameter stimulating electrode comparing with our conventional electrode can elicit electrical evoked potentials in RCS rat as much as our conventional electrode does. Our result suggests that the half diameter of stimulating electrode can be used as minimally invasive stimulating electrode.
|
